Oct 21 2022

Cannabis Extracts May Help Treat Dermatophytosis and Other Skin Diseases

A new study has found that cannabis extracts “may be of value to treat dermatophytosis and other skin diseases caused by various microorganisms.”

Published in the journal  Frontiers in Microbiology, the study was conducted by researchers at the Czech University of Life Sciences Prague and Charles University, both in Czechia.

“Cannabis preparations are gaining popularity among patients with various skin diseases. Due to the lack of scientific evidence, dermatologists remain cautious about their prescriptions”, states the study. “So far, only a few studies have been published about the effects of high-potency cannabis extracts on microorganisms (especially dermatophytes) causing skin problems that affect more than 25% of the worldwide population.”
Continue reading

Oct 21 2022

Some Cannabinoids Have Toxic Effect on Colon Polyps, Says New Study

An International Journal of Molecular Sciences study has found that cannabinoids have a toxic effect on colon polyps, indicating therapeutic potential in battling colon cancer cells.

“Purified cannabinoids have been shown to prevent proliferation and induce apoptosis in colorectal carcinoma cell lines”, claims the abstract of the study. The primary objective was to “assess the cytotoxic effect of cannabinoid extracts and purified cannabinoids on both colorectal polyps and normal colonic cells, as well as their synergistic interaction.”

For the study, various cannabinoid blends were tested to identify the optimal synergistic effect.  Biopsies from polyps and healthy colonic tissue were obtained from 22 patients undergoing colonic polypectomies.
Continue reading

Oct 21 2022

Report: CBD Oil Market Valued at $2.42 Billion, to Grow to Over $15 Billion by 2028

According to a new report by Insight partners, the market for cannabidiol (CBD) oil has grown to $2.42 billion, and is expected to surpass $15 billion within the next six years.

The CBD Oil Market report found that the CBD oil market size is expected to grow from USD 2.42 billion in 2021 to USD 15.66 billion by 2028; it is expected to grow at a compound annual growth rate (CAGR) of 31.2% from 2022 to 2028.

“Aurora Cannabis Inc.; Endoca; Medical Marijuana, Inc.; Nuleaf Naturals, LLC; Elixinol Global Limited; CV Sciences, Inc.; Canopy Growth, and Folium Biosciences are the leading market players profiled during the study”, states the report. “Several other major companies were also analyzed during the course study to get a holistic view of the global CBD oil market.”
Continue reading

Oct 20 2022

Colorado Votes Next Month on Initiative to Legalize Psychedelics

Colorado voters in just 24 days will be deciding whether or not to legalize psychedelics, including licensed healing centers, making them just the second state to do so following Oregon.

Proposition 122 is on the November 8th ballot in Colorado. The measure would decriminalize the possession, cultivation, consumption and sharing (for those aged 21 and older) of the following hallucinogenic/entheogenic plants and fungi, which are currently classified as Schedule I controlled substances under state law:

  • dimethyltryptamine (DMT);
  • ibogaine;
  • mescaline (excluding peyote);
  • psilocybin*; and
  • psilocyn*.
*Hallucinogenic chemicals found in magic mushrooms

Continue reading

Oct 20 2022

Study: Anxiolytic Effects of CBD on Frontline Health Care Workers Maintains for Up to a Month

The anxiolytic (anti-anxiety) effects of CBD in frontline health care professionals during the COVID-19 pandemic were maintained up to 1 month after the treatment discontinuation, “suggesting a persistent decrease in anxiety in this group in the real world”.

This is according to a new study published by the journal Frontiers in Pharmacology, and epublished by the National Institute of Health. The study is titled Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic.

The objective of the study was to “assess whether the effects of oral administration of 300 mg of Cannabidiol (CBD) for 28 days on mental health are maintained for a period after the medication discontinuation.”
Continue reading

Oct 20 2022

Study: Cancer Patients with Refractory Pain May Find Relief With Oral Marijuana Spray

A new study published in the journal PLOS One has found that terminal cancer patients with refractory pain respond favorably to a marijuana spray containing equal parts THC and CBD.

“This pilot study aimed to assess the safety, tolerability, pharmacokinetics and exploratory analgesic effect of a novel water-soluble oro-buccal nanoparticle spray of a cannabis-based medicine in patients with advanced incurable malignancy with unrelieved pain from opioid analgesic”, states the study, which was conducted by researchers at the University of New South Wales and the University of Sydney.

For this multi-stage study, participants received a marijuana spray containing 2.5 mgs of THC and 2.5 mgs of CBD.
Continue reading

Oct 20 2022

Australian Capital Territory Decriminalizes Drug Possession

The Legislative Assembly for the Australian Capital Territory passed legislation today to decriminalize the possession of eight different drugs including MDMA, cocaine, psilocybin and LSD.

The Australian Capital Territory.

The Legislative Assembly for the Australian Capital Territory passed the legislation by a vote of 13 to 6. The measure was introduced by Labor Party MP Michael Pettersson. The Australian Capital Territory houses Canberra, Australia’s capital.

The new law will take effect in October of next year, and will decriminalize the possession of cocaine (1.5 grams), heroin (2 grams), MDMA (3 grams), methamphetamine (1.5 grams), amphetamine (2 grams), psilocybin (2 grams), lysergic acid (2 milligrams) and LSD (2 milligrams). Under the law those caught with these drugs would receive a $100 AUD fine rather than jail time. The fine could be waived if the person voluntarily completes a drug diversion program.
Continue reading

Oct 20 2022

Mission Green Launches Clemency Initiative to Release Parker Coleman, Serving 60 Years for Marijuana

Mission Green announced today the filing of a clemency petition for Parker Coleman, Jr., who is currently serving a 60-year federal sentence for marijuana-related offenses.

This filing along with several other petitions comes on the heels of President Biden’s historic mass pardon of anyone previously convicted on a federal charge of simple possession of marijuana.

Supported by Glass House Brands, Mission Green is working with the Academy for Justice to submit clemency petitions with the hope that the President will follow through on his promise to release those convicted of non-violent marijuana offenses. The submission for Mr. Coleman is part of a new campaign, the Cannabis Clemency Initiative, that seeks to help people still incarcerated on marijuana charges, beginning with those locked up in federal prison. The Initiative brings together criminal justice scholars and reform advocates to achieve its ambitious goals.
Continue reading

Oct 20 2022

Low-Dose THC Has Positive Effect on Morbidity, Quality of Life and Mortality in Geriatric and Palliative Patients

Low-dose THC “has a positive effect on morbidity, side effects, quality of life and mortality in geriatric and palliative patients”, according to a new study.

The study was published by the peer-reviewed journal peer-reviewed journal MMW – Fortschritte der Medizin, as well as on the website for the U.S. National Library of Medicine.

“Cannabis-containing medicines have been successfully used in our practice for more than 20 years in pain and especially in geriatric and palliative patients”, notes the abstract of the study. “While it was initially a very indication-specific use (pain, loss of appetite, etc.) and also with higher THC doses, this changed over time to low THC doses and a therapy focus on suffering-perpetuating symptoms and especially on stress (Matrix of Symptoms).”
Continue reading

Oct 20 2022

Study: THC/CBD Medications Provide Clinical Improvements to Poly Medicated Dementia Patients

A long-term THC/CBD medication “can be administered safely and with overall positive clinical improvement to poly medicated older adults with severe dementia and associated problems.”

This is according to a new study published in the peer-reviewed journal  Frontiers in Aging Neuroscience, and conducted by researchers in Switzerland.

“The management of behavioral symptoms and rigidity in patients with dementia constitutes a significant challenge”, according to researchers. “Short-term studies suggest an interest in the use of medical cannabis, but long-term data are lacking.”

With this in mind, the objective of this study “was to investigate the feasibility and long-term safety of administering tetrahydrocannabinol/cannabidiol (THC/CBD) treatment as an additional drug to a poly medicated population with severe dementia, evaluate clinical improvements, and collect information on the pharmacokinetics of cannabinoids and possible drug-drug interactions.”
Continue reading